innerbuddies gut microbiome testing

Gut Microbiome and Atopic Dermatitis: How Your Allergic Skin Is Influenced

Atopic dermatitis isn’t just a skin problem—it’s closely tied to what’s happening inside your gut. Your gut microbiome, the community of trillions of microbes living in the digestive tract, helps train immune responses and influences the level of inflammation throughout the body. When the balance of beneficial microbes shifts, it can affect how the immune system reacts, making allergic skin symptoms like itching, redness, and flare-ups more likely.

Research suggests that gut microbes may shape atopic dermatitis through several interconnected pathways, including immune signaling, barrier function, and metabolic byproducts. Certain microbes help produce short-chain fatty acids and other compounds that support a calmer immune environment and strengthen gut barrier integrity. A more fragile barrier can allow inflammatory signals to travel more easily, potentially worsening skin inflammation and interfering with the skin barrier’s ability to retain moisture.

The good news: supporting microbiome balance may help support healthier skin from the inside out. By focusing on fiber-rich, microbiome-feeding foods, limiting ultra-processed patterns that can promote dysbiosis, and considering targeted, evidence-informed interventions (such as select probiotics or prebiotics when appropriate), you may help nudge the gut-immune-skin connection toward greater resilience—potentially reducing inflammation drivers that contribute to atopic dermatitis.

Test Your Gut Microbiome for Atopic Dermatitis Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Atopic dermatitis

Atopic dermatitis (eczema) is a chronic inflammatory skin condition marked by itchy, dry patches and barrier dysfunction. It affects many children worldwide and persists into adulthood for some, with roughly 15–20% of children and 1–3% of adults affected. While genetics and skin barrier defects drive disease, evidence increasingly points to the gut–skin axis, where the gut microbiome shapes immune responses and inflammation through metabolites like short-chain fatty acids.

In AD, gut dysbiosis often means reduced diversity and lower SCFA-producing microbes, with some pro-inflammatory taxa elevated. These shifts can weaken the gut barrier, promote systemic inflammation, and contribute to flare frequency and severity. Strategies to rebalance the gut ecosystem—fiber-rich diets, prebiotics, fermented foods when tolerated, and clinician-guided probiotics—can complement skin-focused care and support long-term skin health.

The InnerBuddies test translates gut microbiome data into personalized steps, helping tailor prebiotic and probiotic options to an individual's flare pattern and symptoms. By linking gut ecology to itch, redness, and barrier stability, this approach aims to optimize inflammation control and empower more targeted, patient-specific eczema management.

  • SCFA-producing beneficial microbes (e.g., Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Butyrivibrio spp., Coprococcus comes) help dampen inflammation in atopic dermatitis by supporting regulatory T cells and reducing Th2/Th17 signaling.
  • Loss or reduction of anti-inflammatory residents (Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Bifidobacterium longum, B. breve, Akkermansia muciniphila) lowers SCFA production and shifts immune tone toward pro-allergic pathways, potentially worsening flares.
  • Overabundance of potential pro-inflammatory taxa (Escherichia/Shigella, Streptococcus, Staphylococcus, Bacteroides fragilis group, Collinsella, Ruminococcus gnavus) and overall Proteobacteria increase correlate with higher systemic inflammation and more severe skin symptoms in AD.
  • Dysbiosis-associated gut-barrier disruption (reduced tight-junction support) can increase intestinal permeability, enabling inflammatory signals that aggravate itch and redness in AD.
  • Microbial metabolites like SCFAs from a healthy gut microbiome promote regulatory immune pathways; loss of SCFA-producers can raise inflammatory tone and promote eczema flares.
  • Personalized microbiome insights (e.g., via targeted testing) can guide diet and selective probiotics to boost SCFA producers and curb pro-inflammatory microbes, potentially reducing flare frequency.
Test Your Gut Microbiome for Atopic Dermatitis Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Allergic / atopic

Atopic dermatitis (AD), commonly known as eczema, is a chronic, inflammatory skin condition marked by itchy, dry, and sometimes oozing or scaly patches. While it’s often influenced by genetics and skin barrier function (including lower ceramide levels and impaired barrier “tight junction” integrity), immune dysregulation and environmental triggers also play major roles. Increasingly, research is highlighting that the gut microbiome—the community of microbes living in the digestive tract—can shape immune responses that affect the skin, helping determine whether inflammation escalates or calms.

The gut–skin connection is thought to work through multiple pathways: microbiome diversity and balance influence how the immune system develops and reacts to allergens and inflammatory signals. Certain microbial patterns may promote production of beneficial metabolites (like short-chain fatty acids), which can support regulatory immune pathways and reduce inflammatory signaling. Other microbial shifts may contribute to a more pro-inflammatory immune environment, potentially worsening symptoms. In AD, gut microbial changes have been associated with altered immune tone (including T-helper cell imbalance), increased intestinal permeability in some individuals, and systemic inflammation that can further compromise the skin barrier.

Supporting a healthier gut microbiome may therefore be one strategy to complement conventional eczema care. Approaches often focus on improving microbiome balance—through dietary fiber and fermented foods (when tolerated), ensuring adequate intake of prebiotic substrates that feed beneficial microbes, and discussing targeted probiotic options with a clinician when appropriate. Because individual responses vary and AD flares can be driven by multiple factors, the most effective plan typically combines skin barrier–focused treatments with gut-supportive nutrition and lifestyle habits to help reduce inflammation and support long-term skin health.

  • Itchy, inflamed skin (pruritus)
  • Dry, flaky skin (xerosis) with rough texture
  • Red to rash-like patches, especially during flare-ups
  • Thickened or leathery skin from chronic scratching (lichenification)
  • Oozing, crusting, or weeping lesions during severe flares
  • Recurrent skin irritation in common areas (e.g., face, neck, elbows, knees)
Test Your Gut Microbiome for Atopic Dermatitis Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Atopic dermatitis

This content is most relevant for people living with atopic dermatitis (eczema) who experience persistent itching, inflamed, dry, or flaky skin and want to understand how factors beyond the skin—especially gut health—may influence flare-ups. It’s also helpful for those who notice that their eczema worsens during certain periods (e.g., after dietary changes, stress, or exposure to triggers) and are looking for complementary strategies that may support long-term symptom control.

It’s particularly useful for individuals who have recurrent rashes in common eczema areas such as the face, neck, elbows, and knees, or who deal with more severe flare patterns like oozing, crusting, and weeping lesions. If you’ve struggled with chronic scratching that leads to thickened, leathery skin (lichenification), this topic can offer additional context on how immune signaling and skin barrier function may be affected by gut microbiome balance.

This guidance is also a good fit for readers who want an evidence-informed “gut–skin connection” perspective—especially those interested in improving microbiome diversity and immune regulation through nutrition. For example, it may resonate with people considering dietary fiber, prebiotic foods, and fermented foods (when tolerated), or those who are curious about whether targeted probiotics could be worth discussing with a clinician as part of a broader eczema plan that still prioritizes skin barrier–focused treatments.

Atopic dermatitis (AD) is one of the most common inflammatory skin conditions, affecting a large share of children and a substantial proportion of adults worldwide. Prevalence estimates vary by country, study design, and age group, but AD is widely reported to affect roughly 15–20% of children globally, with many cases beginning in early childhood. In adulthood, AD remains common—often cited at about 1–3% of adults—though rates can be higher in some populations.

AD prevalence also follows a typical age pattern: symptoms often start in infancy or early childhood, and many children improve as they get older, while others continue to have chronic or relapsing disease into adolescence and adulthood. This matters clinically because chronic itch, dry/flaky skin, and recurrent flare-ups (including areas such as the face, neck, elbows, and knees) can persist for years, contributing to ongoing disease burden and affecting quality of life.

The visible symptoms of AD—itchy inflamed patches, xerosis, redness, oozing/crusting during severe flares, and thickened skin from chronic scratching (lichenification)—are therefore not rare experiences for a meaningful portion of the population. Because AD is influenced by a mix of genetic predisposition, skin-barrier function, immune dysregulation, and environmental triggers, the condition’s prevalence remains high across diverse settings, and the global rise in allergic and inflammatory conditions has kept AD as a major public health concern.

Test Your Gut Microbiome for Atopic Dermatitis Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Atopic Dermatitis: How Your Microbiome Impacts Allergic Skin

Atopic dermatitis (eczema) is more than a skin-barrier problem—it also involves immune dysregulation influenced by the gut microbiome. The gut’s microbial diversity and balance help shape immune development and allergic/inflammatory signaling, which can affect how strongly the body responds to triggers. In people with AD, research has observed gut microbial differences alongside immune “tone” changes (such as T-helper imbalance), suggesting that gut ecology may contribute to whether inflammation escalates or stays controlled.

The gut–skin connection may also involve microbial metabolites and gut barrier function. Certain beneficial microbes produce compounds like short-chain fatty acids (SCFAs), which can support regulatory immune pathways and help dampen inflammatory signaling. When the gut microbiome shifts toward less protective patterns, it may contribute to a more pro-inflammatory state and, in some individuals, increased intestinal permeability—sometimes called “leaky gut.” This can allow inflammatory signals to spread systemically, potentially worsening itchy, inflamed, dry skin and flare frequency.

Because AD commonly presents with pruritus, dryness, red rash-like patches, and sometimes weeping or crusting during flares, supporting gut microbiome health may complement standard eczema care. Strategies often include increasing dietary fiber and other prebiotic substrates that feed beneficial microbes, considering fermented foods if tolerated, and discussing targeted probiotics with a clinician when appropriate. While individual responses vary and flares can be driven by multiple factors, improving gut microbial balance may help reduce inflammation and support a healthier immune environment that benefits long-term skin barrier stability.

Test Your Gut Microbiome for Atopic Dermatitis Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Atopic dermatitis

  • Immune dysregulation shaped by gut microbes: gut microbial composition influences T-helper balance (e.g., Th2/Th17 and regulatory T-cell activity), affecting allergic and inflammatory signaling that can worsen atopic dermatitis (AD).
  • Microbial metabolites (especially SCFAs) modulate inflammation: beneficial gut bacteria produce short-chain fatty acids that promote regulatory immune pathways and help dampen pro-inflammatory responses relevant to eczema flares.
  • Intestinal barrier integrity and “leaky gut” effects: dysbiosis can weaken gut tight junctions, increasing intestinal permeability and allowing microbial or inflammatory components to trigger systemic immune activation that can aggravate skin inflammation.
  • Pattern recognition and systemic immune crosstalk: microbial products (e.g., lipopolysaccharide and other immunostimulatory molecules) can alter innate immune signaling and cytokine profiles, indirectly driving itch and inflammatory skin changes.
  • Microbiome-driven control of allergic sensitization: early-life or ongoing gut microbial patterns can influence how strongly the immune system becomes sensitized to allergens, which may increase susceptibility to AD exacerbations.
  • Colonization resistance and reduced pathogenic overgrowth: a diverse, protective microbiome can limit colonization by potentially pro-inflammatory organisms, lowering overall inflammatory tone that contributes to AD severity.

Atopic dermatitis (AD) is shaped not only by skin-barrier defects, but also by immune dysregulation that can be influenced by the gut microbiome. Gut microbial communities help “train” and regulate immune responses, including the balance among T-helper pathways (such as Th2 and Th17) and regulatory T-cell activity. When the gut microbiome is less diverse or shifted away from protective patterns, immune signaling can become more pro-allergic and inflammatory—potentially amplifying the body’s reaction to common flare triggers and making eczema symptoms like redness and itching harder to control.

A key part of the gut–skin connection involves microbial metabolites, especially short-chain fatty acids (SCFAs). Beneficial microbes produce SCFAs that support regulatory immune pathways and help restrain excessive inflammatory responses. If dysbiosis reduces these metabolite-producing populations, inflammatory tone may rise, which can contribute to more frequent or more intense AD flares. In addition, gut microbial products can influence innate immune signaling and cytokine profiles through pattern-recognition pathways, creating systemic immune “crosstalk” that may indirectly worsen itch and inflammation in the skin.

The gut barrier may be another important mechanism. Dysbiosis can impair intestinal tight junctions, increasing permeability (often described as “leaky gut”), which may allow inflammatory components or microbial signals to cross into circulation and trigger broader immune activation. Over time, this systemic inflammatory environment can intensify skin symptoms. Meanwhile, a healthier, more diverse microbiome can provide colonization resistance—limiting overgrowth of potentially pro-inflammatory organisms—and can also affect allergic sensitization, influencing how strongly the immune system reacts to allergens and thus how susceptible a person is to AD exacerbations.

Test Your Gut Microbiome for Atopic Dermatitis Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In atopic dermatitis, gut microbiome studies commonly report an altered community structure compared with people without eczema, often characterized by reduced diversity and shifts in the relative abundance of key bacterial groups. These changes can affect immune “education,” including how readily the body balances T-helper responses (such as Th2/Th17 signaling) versus regulatory T-cell activity. When the gut ecosystem is less diverse or skewed away from anti-inflammatory tendencies, immune signaling may shift toward a more pro-allergic tone, potentially making flare triggers more likely to amplify redness and pruritus.

A recurring theme is disruption of bacteria that normally support healthy metabolite production, particularly short-chain fatty acids (SCFAs). SCFAs such as butyrate and propionate help sustain regulatory immune pathways and can dampen excessive inflammatory responses. In AD-associated dysbiosis, the reduced presence of SCFA-producing taxa may lower these protective metabolites, weakening the immune system’s checks on inflammation. In turn, this can contribute to a systemic inflammatory milieu that indirectly worsens skin barrier dysfunction and the intensity or frequency of eczema flares.

Another microbial pattern linked to atopic dermatitis involves interactions with gut barrier integrity. Dysbiosis may reduce beneficial organisms that help maintain intestinal tight junctions, which can increase permeability and allow inflammatory microbial cues to cross into circulation. This “gut–immune crosstalk” can intensify overall inflammatory activation, reinforcing itch and skin inflammation. At the same time, a healthier, more balanced microbiome can provide colonization resistance against potentially pro-inflammatory overgrowth and may influence allergic sensitization pathways—factors that together shape how readily eczema becomes uncontrolled.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Butyrivibrio spp.
  • Bifidobacterium longum
  • Bifidobacterium breve
  • Akkermansia muciniphila
  • Dialister spp.
  • Coprococcus comes


Elevated / overrepresented taxa

  • Escherichia/Shigella
  • Streptococcus
  • Staphylococcus
  • Bacteroides (genus; e.g., Bacteroides fragilis group)
  • Ruminococcus gnavus group
  • Collinsella
  • Proteobacteria (phylum-level increase; composite signal)


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis pathways (butyrate/propionate production)
  • Tight junction maintenance and gut barrier integrity pathways (intestinal permeability control)
  • Bile acid metabolism and secondary bile acid production (FXR/TGR5-linked immune modulation)
  • Microbial metabolism of tryptophan and aryl hydrocarbon receptor (AhR) signaling (immune education)
  • Regulation of T-helper balance (Th2/Th17) and regulatory T-cell (Treg) induction via microbial metabolites
  • Pattern recognition receptor (TLR/NOD-like receptor) signaling influenced by microbial-associated molecular patterns (MAMPs)
  • Bacterial fermentation of dietary fibers and generation of immunomodulatory metabolites (SCFAs/other fermentation products)
  • Inflammatory epithelial-microbe crosstalk and cytokine signaling (e.g., IL-4/IL-13, IL-17, TNF pathways)


Diversity note

In people with atopic dermatitis (eczema), gut microbiome studies commonly show reduced overall microbial diversity and an altered community structure compared with individuals without eczema. Rather than a single “bad germ,” the pattern is usually a shift in the relative abundance of multiple bacterial groups, which can change how the immune system matures and regulates inflammatory responses. This altered microbial ecosystem may tilt immune signaling toward a more pro-allergic or pro-inflammatory balance, helping explain why some people experience flares that seem to intensify itch and redness in response to everyday triggers.

A frequent theme in AD-associated dysbiosis is disruption of microbes that support anti-inflammatory metabolite production—especially short-chain fatty acids (SCFAs) like butyrate and propionate. When diversity decreases and SCFA-producing populations are less abundant, protective signals that normally promote regulatory immune pathways can weaken. The result is often a “less buffered” inflammatory state, where systemic immune tone is more easily pushed toward inflammation, indirectly contributing to skin barrier instability and flare susceptibility.

Gut barrier function is another way diversity changes can matter. In some individuals with atopic dermatitis, lower diversity and community imbalance may coincide with impaired intestinal tight-junction integrity, increasing permeability. This can enhance gut–immune crosstalk by allowing inflammatory cues to influence immune activation beyond the gut. Over time, these dynamics can reinforce an unfavorable inflammatory environment while also reducing colonization resistance against less beneficial or pro-inflammatory overgrowth.


Test Your Gut Microbiome for Atopic Dermatitis Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic approaches often fail for atopic dermatitis because eczema is driven by more than a single, skin-only problem. Even when two people have similar-looking flare patterns, their underlying drivers can differ—immune dysregulation, barrier dysfunction, and gut–immune signaling may not be operating to the same degree. As a result, broad recommendations (or one-size-fits-all “anti-inflammatory” plans) may not correct the specific immune “tone” shifts that are being influenced by each person’s gut microbiome composition and diversity.

    Another reason generic solutions underperform is that the gut microbiome effects are not simply “more probiotics = better.” In atopic dermatitis, studies commonly show reduced microbial diversity and fewer bacteria that generate protective metabolites like short-chain fatty acids (SCFAs). If the diet and overall gut environment don’t support SCFA-producing taxa, many standard probiotic strategies may provide only temporary, inconsistent changes. Without adequate prebiotic substrates (fiber types and fermentation-supporting nutrients) and consistent dietary patterns, introduced microbes may not establish well or may not produce the metabolite outputs that help support regulatory immune pathways.

    Finally, many generalized plans overlook gut barrier integrity and the gut–immune “crosstalk” aspect of eczema flares. When intestinal permeability is elevated, inflammatory cues can circulate more easily and amplify skin inflammation, itching, and flare frequency. Generic regimens that don’t address the specific diet–microbiome interactions, tolerability issues (e.g., fermented foods triggering symptoms in some individuals), or personalized trigger context may fail to reduce permeability-related signaling. The variability in individual microbiome, food response, and immune susceptibility means that standardized interventions often miss the mechanisms most relevant to an individual’s flare escalation.

  • Common mistakes

    • Using one-size-fits-all advice that targets only the skin (e.g., generic “anti-inflammatory” or “eczema cleansers”) while ignoring immune tone shifts (Th2/Th17 vs Treg balance) that may be influenced by gut ecology.
    • Assuming that “more probiotics always helps,” despite AD often involving reduced SCFA-producing taxa; without supporting fermentation substrates, introduced microbes may not persist or produce enough butyrate/propionate.
    • Failing to address low microbial diversity and the underlying diet pattern; generic plans may add supplements without correcting low-fiber intake or inconsistent eating that prevents SCFA production.
    • Skipping prebiotic/substrate planning (fiber types and fermentation-supporting nutrients), leading to probiotics that don’t generate the metabolite outputs needed for regulatory immune signaling.
    • Overlooking gut barrier integrity and gut–immune crosstalk (intestinal permeability); generic approaches may not consider factors that increase permeability and amplify inflammatory signals to the skin.
    • Ignoring individual food triggers and tolerability; some people with AD worsen with certain fermented foods or specific carbohydrate patterns, so broad “eat these” guidance can backfire.
    • Not assessing symptom timing and flare context (e.g., whether flares correlate with dietary changes, GI symptoms, or antibiotic/probiotic history), resulting in interventions that don’t match the patient’s true mechanism.
    • Relying on short-term trials without adequate duration or consistency; gut microbiome and immune signaling shifts typically require sustained dietary and microbial-pressure changes to stabilize.

What to do

  • General support strategies

    Atopic dermatitis (AD) is influenced by more than skin barrier dysfunction—immune signaling and the gut microbiome also play meaningful roles. A diverse, balanced gut ecosystem can help “train” immune pathways and promote a more regulated inflammatory tone, which may affect how strongly the body reacts to triggers that worsen eczema. When gut microbial balance shifts, the resulting pro-inflammatory signaling may contribute to more frequent or intense flare-ups in some people.

    Supporting gut microbiome health often begins with diet strategies that feed beneficial microbes. Increasing dietary fiber from a variety of plant foods can encourage the growth of bacteria that produce helpful metabolites such as short-chain fatty acids (SCFAs), which are linked to regulatory immune activity and dampening of excessive inflammation. Prebiotic substrates (like those found in legumes, oats, onions, garlic, and other fiber-rich foods) can be particularly useful because they act as fuel for protective microbes rather than introducing new organisms directly.

    For additional support, some individuals may tolerate fermented foods (such as yogurt with live cultures, kefir, sauerkraut, kimchi, or tempeh), which can help diversify the gut ecosystem. Targeted probiotics may also be considered, ideally in consultation with a clinician—especially when symptoms, medication use, or sensitivities suggest that a more individualized approach is needed. Because gut barrier function and microbial metabolites can influence systemic inflammation, gradual dietary changes and attention to personal tolerance may help complement standard eczema care and support longer-term skin stability.

  • Lifestyle recommendations

    • Increase dietary fiber (e.g., legumes, oats, whole grains, fruits, vegetables) to support a more diverse gut microbiome and promote beneficial SCFA production.
    • Consider gut-friendly prebiotics and fermented foods if tolerated (e.g., yogurt/kefir with live cultures, sauerkraut, kimchi) and introduce gradually to monitor eczema/flaring.
    • Prioritize a balanced, anti-inflammatory diet pattern (more plants/omega-3 sources like fatty fish or flax/chia; limit ultra-processed foods and added sugars).
    • Avoid known personal triggers that worsen symptoms (common examples include certain foods in sensitive individuals, stress, smoke exposure, and overheating/sweating) and keep a symptom-food diary.
    • Support gut and skin barrier health by maintaining good hydration and using gentle skin care (short lukewarm showers, fragrance-free moisturizers), which may reduce flare severity alongside gut-focused habits.
    • Discuss evidence-based probiotic options with a clinician if you want to try targeted strains, especially during/after antibiotic use or during persistent flares.

  • Nutrition recommendations

    • Increase dietary fiber (aim for a gradual, daily rise toward ~25–38 g/day depending on size/guidelines) from oats, legumes, fruits, vegetables, and whole grains to support beneficial gut bacteria and SCFA production.
    • Add prebiotic-rich foods such as onions, garlic, leeks, asparagus, chicory root, bananas (slightly underripe), and cooked-then-cooled potatoes/rice to selectively feed anti-inflammatory microbiota.
    • Include fermented foods if tolerated—e.g., yogurt with live cultures, kefir, sauerkraut, kimchi, and miso—to promote microbial diversity and potentially improve immune regulation relevant to atopic dermatitis.
    • Choose an anti-inflammatory diet pattern: emphasize extra-virgin olive oil, fatty fish (salmon/sardines), nuts, and seeds; limit ultra-processed foods and excess added sugars that can shift the microbiome toward a more inflammatory profile.
    • Consider omega-3 fats to support immune balance: include fatty fish 2–3x/week or discuss an omega-3 supplement with a clinician if fish intake is low.
    • Support gut barrier health with adequate micronutrients and hydration: ensure sufficient protein, zinc, vitamin D, magnesium, and vitamin A from whole foods (or supplementation if labs/clinician indicate), while maintaining regular fluid intake.
    • If flares correlate with certain foods, consider a short, clinician-guided elimination trial (especially for common triggers like egg, milk, wheat, soy, peanuts, or shellfish) rather than broad restrictions—then reintroduce to avoid unnecessary microbiome disruption.

  • Supplement considerations

    For atopic dermatitis, gut-focused supplements are often considered as an adjunct to standard eczema care because the gut microbiome can influence immune balance and inflammatory signaling that affect skin flare severity. In people with AD, research suggests differences in microbial diversity alongside immune “tone” shifts (for example, T-helper imbalance). Supporting a more favorable microbial ecosystem may help encourage more regulatory pathways and potentially reduce the tendency for inflammation to escalate in response to triggers.

    Several categories of supplements are commonly discussed for this purpose. Prebiotic fibers and other fermentable substrates can act as fuel for beneficial microbes, which may increase production of short-chain fatty acids (SCFAs). SCFAs are important metabolites that support regulatory immune function and may help dampen pro-inflammatory signaling relevant to itching and redness. Some individuals also explore probiotics or targeted strains, ideally selected based on evidence for immune modulation and skin outcomes, though response can be individual and should be approached thoughtfully—particularly for those with active, severe symptoms or complex medical histories.

    Because the gut–skin connection may also involve gut barrier integrity, supplements that promote gut barrier health and reduce harmful microbial shifts may be relevant. This includes maintaining adequate fiber intake and considering fermented foods or probiotic-containing options if tolerated, while monitoring for symptom changes during flares. It’s also important to use supplements strategically (rather than “stacking” multiple new products at once), follow clinician guidance, and recognize that AD flares can be driven by many factors beyond the microbiome alone.

  • Retesting / monitoring note

    For atopic dermatitis, retesting recommendations typically focus on reassessing gut–immune alignment rather than only rechecking a single skin trigger. Since gut microbial diversity and the balance of immune signaling can shift over time in response to diet, medications, antibiotics, stress, and inflammation itself, clinicians often consider repeat evaluation after an intervention window (commonly several weeks to a few months) to see whether intestinal ecology and related immune “tone” are moving in a more anti-inflammatory direction. Retesting can help determine whether changes in fiber intake, prebiotic support, fermented-food tolerance, or probiotic use are associated with steadier inflammatory signaling—information that may correlate with fewer or less intense eczema flares.

    When retesting is considered, it’s also important to align timing with real-life flare patterns and treatment stability. If someone is actively flaring or has recently used systemic steroids, antibiotics, or other agents that significantly alter the microbiome, results may reflect temporary perturbations. Many clinicians therefore prefer to retest when eczema management is relatively stable (or after a washout period when appropriate) to better interpret gut microbiome signals. This can clarify whether the gut barrier function markers and metabolite-related pathways (such as short-chain fatty acid–associated effects) are recovering, which may support improved skin barrier performance and less pruritus.

    Finally, retesting should be framed as iterative, personalized monitoring. Because responses vary widely across individuals, re-evaluation is most useful when paired with ongoing symptom tracking (itch score, sleep disruption, flare frequency, and severity) and dietary adherence. If retesting suggests persistent dysbiosis or ongoing pro-inflammatory patterns, the next step may involve adjusting prebiotic fiber targets, refining food tolerability, or discussing targeted probiotics with a qualified clinician—then repeating assessment again after another structured interval.

The importance of gut microbiome testing

  • Why testing matters

    For atopic dermatitis, gut microbiome testing can matter because eczema isn’t driven by the skin barrier alone—immune signaling and inflammatory “tone” are also influenced by gut ecology. Research links AD with measurable differences in gut microbial balance and activity, which can affect how the immune system develops and responds to triggers. By looking beyond symptoms and assessing what’s happening in the gut ecosystem, testing may help clarify whether a patient’s pattern of inflammation could be supported by microbiome-targeted strategies alongside standard skincare and treatment.

    Microbiome testing can also provide insight into gut-barrier–related factors that may influence flare frequency and severity. Certain beneficial microbes help generate protective metabolites such as short-chain fatty acids (SCFAs), which support regulatory immune pathways and may help dampen excessive inflammation. When stool testing suggests reduced diversity or fewer “fiber/SCFA-supporting” microbes, it can signal a potential need to adjust diet or supplementation to promote more anti-inflammatory signaling. This is especially relevant for individuals who experience frequent flares, food-related symptom variability, or concurrent gastrointestinal complaints.

    Importantly, testing can help personalize next steps rather than relying on generic recommendations. Because gut microbiomes vary widely between people, two patients with the same eczema symptoms may respond differently to probiotics, prebiotics, or fermented foods. A results-informed approach can guide more targeted choices—such as increasing specific prebiotic fibers, correcting under-supported microbial functions, or discussing tailored probiotic options with a clinician—while monitoring whether gut-directed changes correlate with improved itch, skin stability, and reduced inflammatory escalation.

  • How InnerBuddies helps

    For atopic dermatitis, the InnerBuddies test can help connect eczema symptoms to potential gut-driven immune and inflammatory patterns. Because AD involves more than a skin-barrier issue—there’s often an immune “tone” component shaped by the microbiome—stool-based insights may reveal whether your gut ecosystem shows signs of lower microbial diversity, less favorable microbial balance, or reduced activity linked to anti-inflammatory signaling. Understanding those underlying gut patterns can help explain why some triggers lead to stronger or longer flares in certain individuals even when standard skincare is in place.

    InnerBuddies can also inform whether microbiome functions that support gut-barrier health and regulatory pathways may be under-supported. Beneficial gut microbes produce metabolites such as short-chain fatty acids (SCFAs), which are associated with more balanced immune responses and calmer inflammation. If testing suggests fewer SCFA-supporting patterns or a shift toward a more pro-inflammatory gut profile, it can guide more targeted next steps—such as increasing specific prebiotic fibers and other microbiome “fuel” through diet, or considering fermented foods if tolerated—to better support regulatory signaling that may complement eczema care.

    Just as importantly, InnerBuddies supports personalization rather than one-size-fits-all recommendations. Since gut microbiomes vary widely, two people with similar eczema symptoms may need different dietary fibers, prebiotic strategies, or clinician-guided probiotic options. By pairing the results with your flare pattern (itch intensity, frequency, and any GI symptoms), you can make gut-focused adjustments with clearer rationale—and monitor whether changes in gut ecology correlate with improved skin stability and fewer inflammatory escalations over time.

Medical Evidence

  • Scientific evidence level

    2 [weak; emerging but inconsistent—mostly association/biologic plausibility with limited causality and no validated clinical utility]

  • Clinical relevance note

    Current clinical relevance is low. While the gut microbiome is biologically plausible as a contributor to immune maturation and systemic inflammation relevant to atopic dermatitis, the human evidence base does not yet support using microbiome profiling for diagnosis, severity grading, risk prediction, or treatment selection. Reported microbial differences are often statistically detectable but not reliably reproducible across populations, and they have not been translated into validated, externally robust clinical algorithms.

    At present, the most defensible stance is that gut microbiome involvement remains a hypothesis with emerging supportive data: associations are repeatedly reported (though inconsistently), longitudinal signals suggest potential early-life relevance, and preclinical work supports mechanistic pathways. However, limitations in observational design (confounding, reverse causality), methodological heterogeneity (batch effects, analytic pipelines), and insufficient/heterogeneous intervention trials mean there is not enough evidence for actionable, microbiome-targeted clinical interventions specifically for AD beyond standard care. Further well-powered, rigorously standardized RCTs (with clinically meaningful endpoints) and externally validated predictive models would be needed to upgrade evidence to a level where microbiome assessment could be considered clinically useful.

Title Journal Year Link
Microbiome and atopic dermatitis: a systematic review and meta-analysis Frontiers in Immunology 2023 View →
Gut microbiota and atopic dermatitis in early life: a systematic review and meta-analysis Journal of Dermatological Science 2022 View →
Probiotics and prebiotics for preventing atopic dermatitis: an updated systematic review and meta-analysis JAMA Network Open 2020 View →
Fecal microbiota signatures in infants with atopic dermatitis Journal of Allergy and Clinical Immunology 2018 View →
Microbiome and risk of atopic dermatitis in early childhood: longitudinal analysis of stool microbiota Nature Communications 2017 View →

Frequently Asked Questions

    ¿Qué es la dermatitis atópica y cómo se relaciona con el microbioma intestinal?
    La AD es una afección cutánea crónica; el microbioma intestinal puede influir en la respuesta inmunitaria y la inflamación, afectando la piel.
    ¿Puede mejorar la salud intestinal reducir las brotes de eccema?
    Podría ayudar como complemento de la atención habitual; las respuestas varían; mantener el cuidado de la piel y consultar a un profesional.
    ¿Qué cambios dietéticos pueden apoyar un microbioma intestinal saludable en AD?
    Aumentar la fibra y los prebióticos; alimentos fermentados si se toleran; personalizar con un profesional de la salud.
    ¿Son útiles los probióticos para la AD?
    En algunas personas sí, bajo supervisión; no son una solución universal.
    ¿Cuáles son los síntomas comunes de la AD?
    Picor, piel seca, erupciones rojas; engrosamiento de la piel por rascado; secreción o costras en brotes graves; áreas comunes.
    ¿Qué tan frecuente es la AD?
    Muy común en niños (aprox. 15-20%), y en adultos alrededor de 1-3%; suele empezar en la infancia.
    ¿Qué es el eje intestino–piel explicado de forma simple?
    Los microbios intestinales influyen en el equilibrio inmunitario y la inflamación, afectando la salud de la piel.
    ¿Qué son los SCFA y por qué importan?
    Ácidos grasos de cadena corta, metabolitos de bacterias intestinales que ayudan a regular la inmunidad y reducir la inflamación.
    ¿Esta implicada la permeabilidad intestinal (“fuga intestinal”) en la AD?
    Puede ocurrir en algunas personas; no es una explicación universal.
    ¿Cómo podrían ayudar las pruebas del microbioma en el manejo de la dermatitis?
    Pueden ofrecer información sobre la ecología intestinal y guiar discusiones sobre dieta o probióticos.
    ¿Qué es la prueba de microbioma InnerBuddies?
    Una prueba de heces que evalúa patrones bacterianos y ayuda a orientar los próximos pasos.
    ¿Qué cambios podría sugerir la prueba?
    Ajustes en la ingesta de fibra y prebióticos, posibles probióticos específicos, seguimiento de los síntomas de la piel.
    ¿Las pruebas del microbioma son seguras y confiables?
    No invasivas; los resultados varían; interpretarlas con un profesional.
    ¿Cómo combinar el cuidado de la barrera cutánea con estrategias para el microbioma?
    Continúa con las cremas hidratantes y barreras; combínalo con una dieta amiga del microbioma y hábitos saludables; vigila las brotes.
    ¿Qué disparadores debo comentar con mi médico?
    Irritantes, alérgenos, estrés, cambios climáticos, infecciones, desencadenantes alimentarios, síntomas GI.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -